Pattern formation during insect leg segmentation: Studies with a prepattern of a cell surface antigen

1991 ◽  
Vol 199 (8) ◽  
pp. 476-491 ◽  
Author(s):  
Betty A. Norbeck ◽  
Jeffrey L. Denburg
Keyword(s):  
Pattern Formation ◽  
Cell Surface ◽  
Surface Antigen ◽  
Cell Surface Antigen ◽  
A Cell

A cell surface antigen expressed by astrocytes and their precursors

Glia ◽  
1993 ◽  
Vol 8 (1) ◽  
pp. 20-32 ◽  
Author(s):  
Vilma Szigeti ◽  
Robert H. Miller
Keyword(s):  
Cell Surface ◽  
Surface Antigen ◽  
Cell Surface Antigen ◽  
A Cell

Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis

2002 ◽  
Vol 30 (6) ◽  
pp. 537-545 ◽  
Author(s):  
Reiner Lammers ◽  
Christina Giesert ◽  
Frank Grünebach ◽  
Anke Marxer ◽  
Wichard Vogel ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Surface ◽  
Surface Antigen ◽  
Adhesion Molecule ◽  
Cellular Adhesion ◽  
Cell Surface Antigen ◽  
Cellular Adhesion Molecule ◽  
A Cell

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

1993 ◽  
Vol 11 (4) ◽  
pp. 738-750 ◽  
Author(s):  
E Oosterwijk ◽  
N H Bander ◽  
C R Divgi ◽  
S Welt ◽  
J C Wakka ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Monoclonal Antibody ◽  
Cell Surface ◽  
Cell Carcinoma ◽  
Surface Antigen ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Surface Antigen ◽  
Human Renal Cell Carcinoma ◽  
A Cell

PURPOSE To define the imaging and biodistribution characteristics of iodine 131-labeled monoclonal antibody (mAb) G250 (131I-mAbG250), which recognizes a cell-surface antigen expressed by human renal cell carcinoma (RCC). PATIENTS AND METHODS G250 is a cell-surface antigen recognized by mAbG250 expressed by RCC but not detected in normal kidney. Clear-cell RCC, the most frequent form of RCC, shows homogeneous expression of G250, whereas non-clear-cell RCC and cancers derived from other organs generally do not express G250. Expression in normal tissues is highly restricted and limited to large bile ducts and gastric epithelium. 131I-mAbG250 was administered intravenously (IV) to 16 patients with RCC 7 to 8 days before surgery at five dose levels, with at least three patients entered at each dose level. RESULTS Clear tumor images were observed in 12 patients with G250-positive tumors and in one of three patients with G250-negative tumors. Imaged lesions in the peritoneal cavity were confirmed at surgery. The smallest lesion visualized was 8 mm in diameter. The specificity of 131I-mAbG250 localization to tumor tissue was established by radioactivity measurements, autoradiography, and immunohistochemistry of biopsied tissues, and technetium 99-human serum albumin blood-flow studies. The fraction of the injected 131I-mAbG250 dose per gram tumor (%ID/g tumor) localized in G250-positive tumors showed a broad range, but reached levels as high as 0.02% to 0.12%. CONCLUSION 131I-mAbG250 localized specifically to G250 antigen-positive RCC and seems to have considerable potential as an imaging agent in RCC patients. 131I-mAbG250 uptake in the tumors, relative as well as absolute, are among the highest reported for tumor biopsies obtained 8 days after IV mAb administration. Based on the specific localization and high accumulation, mAb G250 may have therapeutic potential.

Sign in / Sign up

Export Citation Format

Share Document